Marta Santaliestra

Terrassa, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera.

Journal: Blood cancer journal
Published: January 30, 2026

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Mutational profile and cardiovascular risk factors impact prognosis in triple-negative essential thrombocythemia.

Journal: Leukemia
Published: January 23, 2026

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

Journal: HemaSphere
Published: September 04, 2025

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study.

Journal: Blood cancer journal
Published: December 15, 2024

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.

Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma.

Journal: Annals of hematology
Published: October 29, 2024

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia.

Journal: Leukemia
Published: July 12, 2024

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib.

Journal: Annals of hematology
Published: May 28, 2024

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing.

Journal: Cancers
Published: June 14, 2023

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors.

Journal: Cancers
Published: January 17, 2023

Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia.

Review of the risk of thrombosis or bleeding upon abrupt anagrelide discontinuation in patients with essential thrombocythemia.

Journal: Annals of hematology
Published: July 25, 2022

Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.

Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach.

Journal: Mycopathologia
Published: April 04, 2020

Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report.

Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report.

Journal: Clinical case reports
Published: September 25, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026